Furthermore, our data from in vitro overexpression in HEK293 cells show that the p.Arg1067Gln variant stimulates LRRK2 activity even more than the p.Gly2019Ser variant, suggesting that PD patients with this variant should be considered for ongoing LRRK2 clinical trials with kinase inhibitors. This evidence concerns the gene LRRK2 and Parkinson disease.